News
16th April 2013
AM IMPAKT – New clinical trial investigates apomorphine injection for resolving debilitating morning akinesia in Parkinson’s disease patients
AM IMPAKT, short for Apokyn for Motor IMProvement of Morning AKinesia Trial, is a Phase IV, multi-center, open-label study investigating treatment with APOKYN (APO-go/Apomine) injection to achieve rapid and reliable improvement of motor symptoms in Parkinson’s disease (PD) patients who experience delayed onset of their oral levodopa medication taken upon awakening. A sub-study will also investigate how gastrointestinal (GI) symptoms, commonly experienced by PD patients, may contribute to this delayed onset of effect.... read more
11th April 2013
Britannia Pharmaceuticals launch theparkinsonhub
World Parkinson’s Day 2013 sees the official launch of theparkinsonhub (www.theparkinsonhub.com), an innovative, interactive resource for patients and carers. theparkinsonhub, developed by Britannia Pharmaceuticals, is committed to sharing the latest news and best practice about Parkinson’s disease (PD), with an emphasis on and around mid to late stage PD. read more...
March 2013
New International Marketing Director for Britannia Pharmaceuticals
Britannia Pharmaceuticals (part of the STADA Arzneimittel group of companies) has appointed Robert Wood as Marketing Director, for international markets. read more....
October 2012
Experts at EFNS 2012 symposium believe earlier initiation of continuous dopaminergic stimulation (CDS) therapy is beneficial in advanced Parkinson's disease (PD) read more....
Read the full web report on this symposium
June 2012
Webinar with EURO-INF Project Leader Professor K Ray Chaudhuri discloses significant benefits of apomorphine and intrajejunal levodopa infusion in advanced Parkinson's disease. read more
May 2012
APO-go: simplifying the challenge of Parkinson's therapy in advanced disease. read more
October 2011
New team members are now in place at Britannia Pharmaceuticals Limited. Our new Head of International Marketing Co-ordination, Veronica Guijarro joined Britannia in July 2011 relocating from her native Spain. Veronica has also lived and worked in Paris. Our new Director Partners Europe Middle East and Africa, Robert Wood joined in October 2011. Robert will be responsible for all facets of the Partner relationships in two continents. Both can be reached via the Contact Us page or on +44 1635 568400.
January 2011- Expanding our partnership network
Britannia Pharmaceuticals are pleased to announce that Care4Pharma have become our latest partner. Care4Pharma is the international roll-out of the Dutch company ApotheekZorg and is set to promote Britannia products across Switzerland. This is a welcome return for some of Care4pharma's key personnel that have many years experience working as part of the APO family.
Britannia Pharmaceuticals Ltd have committed to exhibiting at two shows in the first quarter of 2011. We will be attending the 1st Meeting of WFN & ANEI Parkinson's Disease & Movement Disorders, taking place 8th-9th January 2011 at the Sheraton Hotel in Kolkata and the AOPMC 2011 show taking place March 25th-27th in Taipei. The website for the AOPMC Congress is:http://www.aopmc2011taiwan.com/
New team in place at Britannia Pharmaceuticals Limited following it's integration with Genus Pharmaceuticals in Newbury. Visit the Contact Us page to view our new contact details.
Upcoming Events
Britannia are planning a large congress presence in 2013. More details can be found on the links below.
Our Programme of Events for 2013 is as follows:
MDS 2013, Sydney - 16th-20th June
WCN 2013, Vienna - 21st-26th Sept
WPC 2013, Montreal - 1st-4th Oct
WFN 2013, Geneva - 8th-11th Dec
